Skip to content

Newsroom

type
year
Illustration image.png

Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies

11/19/2024 Press release
Illustration image.png

Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024

10/15/2024 Press release
Illustration image.png

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

10/14/2024 Press release
Illustration image.png

Orion’s near-term climate targets approved by the Science Based Targets initiative

9/30/2024 Press release
Illustration image.png

Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster

9/26/2024 Press release
Illustration image.png

Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology

9/25/2024 Press release
Illustration image.png

Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer

9/16/2024 Press release
Illustration image.png

Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024

7/25/2024 Press release
Illustration image.png

Orion is developing the Finnish life science industry in a unique collaboration project

6/3/2024 Press release
Illustration image.png

Orion publishes Interim Report for January–March 2024 and holds a webcast on 25 April 2024

4/11/2024 Press release
Illustration image.png

The change negotiations concerning Orion’s Kuopio plant have been concluded – the company has decided to continue to explore the outsourcing of production at the plant

3/22/2024 Press release
Illustration image.png

Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally

2/22/2024 Press release
Illustration image.png

Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland

2/19/2024 Press release
Illustration image.png

Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024

1/29/2024 Press release
Illustration image.png

Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain

1/29/2024 Press release
Illustration image.png

Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024

1/26/2024 Press release
Illustration image.png

Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs

1/8/2024 Press release
Illustration image.png

Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer

1/5/2024 Press release